News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genentech, Inc. (DNA) And Biogen Idec, Inc. (California) (BIIB) Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia


5/20/2009 9:25:21 AM

SOUTH SAN FRANCISCO, Calif.& CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc. and Biogen Idec (Nasdaq:BIIB) today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan® (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL). The companies will request a priority review, and if granted, anticipate the FDA will make a decision within six months.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES